BR0010604A - Uso de phyllanthus para o tratamento de processos inflamatórios e fibróticos crÈnicos - Google Patents

Uso de phyllanthus para o tratamento de processos inflamatórios e fibróticos crÈnicos

Info

Publication number
BR0010604A
BR0010604A BR0010604-6A BR0010604A BR0010604A BR 0010604 A BR0010604 A BR 0010604A BR 0010604 A BR0010604 A BR 0010604A BR 0010604 A BR0010604 A BR 0010604A
Authority
BR
Brazil
Prior art keywords
phyllanthus
treatment
chronic inflammatory
fibrotic processes
inhibition
Prior art date
Application number
BR0010604-6A
Other languages
English (en)
Inventor
Hildebert Wagner
Angelika Vollmar
Michael Manns
Rolf Gebhardt
Matthias Bahr
Gayane Hrachia Buniatian
Original Assignee
Cmi Ct For Medical Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cmi Ct For Medical Innovation filed Critical Cmi Ct For Medical Innovation
Publication of BR0010604A publication Critical patent/BR0010604A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Patente de Invenção: "USO DE PHYLLANTHUS PARA O TRATAMENTO DE PROCESSOS INFLAMATóRIOS E FIBRóTICOS CRÈNICOS". A presente invenção refere-se ao uso de Phyllanthus para a prevenção ou tratamento de proliferações do tecido conectivo, para a manutenção do nível de glutationa reduzido, para inibição da sintase de óxido nítrico (NOS) induzida por lipopolissacarídeo LPS e para a inibição da expressão da proteína de ciclooxigenase (COX-2).
BR0010604-6A 1999-04-29 2000-04-28 Uso de phyllanthus para o tratamento de processos inflamatórios e fibróticos crÈnicos BR0010604A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19919585A DE19919585A1 (de) 1999-04-29 1999-04-29 Verwendung von Phyllanthus zur Behandlung von oxidativem Streß und anderen Symptomen
PCT/EP2000/003869 WO2000066134A1 (de) 1999-04-29 2000-04-28 Verwendung von phyllanthus zur behandlung von chronisch entzündlichen und fibrotischen prozessen

Publications (1)

Publication Number Publication Date
BR0010604A true BR0010604A (pt) 2002-02-05

Family

ID=7906333

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0010590-2A BR0010590A (pt) 1999-04-29 2000-04-28 Emprego de filanto para estimulação objetivada do sistema imunológico
BR0010604-6A BR0010604A (pt) 1999-04-29 2000-04-28 Uso de phyllanthus para o tratamento de processos inflamatórios e fibróticos crÈnicos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR0010590-2A BR0010590A (pt) 1999-04-29 2000-04-28 Emprego de filanto para estimulação objetivada do sistema imunológico

Country Status (13)

Country Link
US (1) US6586015B1 (pt)
EP (2) EP1176972A1 (pt)
JP (2) JP2002543140A (pt)
CN (2) CN1352563A (pt)
AT (1) ATE275411T1 (pt)
AU (2) AU4559300A (pt)
BR (2) BR0010590A (pt)
CA (2) CA2372223A1 (pt)
DE (2) DE19919585A1 (pt)
ES (1) ES2226831T3 (pt)
MX (2) MXPA01010982A (pt)
PT (1) PT1176971E (pt)
WO (2) WO2000066134A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10030139A1 (de) * 2000-06-20 2002-01-10 Cmi Ag Verwendung von Phyllanthusbesandteilen zur Behandlung oder Prophylaxe von Infekten durch Flaviviridae
ATE275413T1 (de) * 2000-10-06 2004-09-15 Phytrix Ag Verfahren zur herstellung von phyllanthusextrakten
EP1333848B1 (en) * 2000-10-06 2006-04-05 Phytrix AG Phyllanthus-derived compounds for the prevention and/or treatment of diseases associated with a retrovirus
DE10120627A1 (de) * 2001-04-26 2002-10-31 Cmi Ag Verwendung von Phyllanthusbestandteilen zur Behandlung oder Prophylaxe von Infekten durch Hepatitis B-Viren
US20050064053A1 (en) * 2002-11-08 2005-03-24 Em Industries Enriched aqueous components of emblica officinalis
JP2006514670A (ja) 2003-03-03 2006-05-11 稲畑香料株式会社 血清高比重リボタンパク質を増加させるための方法及び技術
JP5508656B2 (ja) * 2004-07-16 2014-06-04 太陽化学株式会社 最終糖化産物生成阻害組成物
TW200607517A (en) * 2004-08-17 2006-03-01 Hepaguard Biotechnology Int L Co Ltd Medicinal composition capable of suppressing proliferation or metastasis of tumor cells
WO2006131932A1 (en) * 2005-06-09 2006-12-14 Mmi Corporation Herbal formulation capable of preventing alcohol-induced hangover, methods of preparing the same and use thereof
US7597910B2 (en) * 2005-08-20 2009-10-06 Slgm Medical Research Institute Compositions and methods for treating prostate disorders
EP2175871B1 (en) * 2007-07-18 2016-08-31 Council of Scientific & Industrial Research A synergistic herbal composition for treatment of rheumatic and musculo-skeletal disorders (rmsds)
DE102007044487A1 (de) * 2007-09-18 2009-04-02 Universität Leipzig Verwendung des umgekehrten Zelldifferenzierungsprogramms (OCDP) zur Behandlung degenerierter, im pathologischen Zustand befindlicher Organe
US20110009692A1 (en) * 2007-12-26 2011-01-13 Yossi Gross Nitric oxide generation to treat female sexual dysfunction
US20090198271A1 (en) * 2008-01-31 2009-08-06 Rainbow Medical Ltd. Electrode based filter
US7749284B2 (en) * 2008-04-28 2010-07-06 Aveda Corporation Oxidative hair dye compositions, methods and products
EP2116253A1 (en) * 2008-05-07 2009-11-11 Phytrix JV, LLC Novel phyllanthus extract
US8916209B2 (en) * 2009-10-02 2014-12-23 Johnson & Johnson Consumer Companies, Inc. Extracts of Phyllanthus niruri
US20110202108A1 (en) * 2010-02-18 2011-08-18 Rainbow Medical Ltd. Electrical menorrhagia treatment
US20130064912A1 (en) * 2011-09-09 2013-03-14 Jon Barron Formulation for alleviation of kidney stone and gallstone symptoms
IN2013CH04565A (pt) 2013-10-08 2015-09-25 Benny Antony
US10286022B2 (en) 2013-10-08 2019-05-14 Benny Antony Medicinal composition of extract of seed of emblica officinalis and method of preparing the same
CN105168314A (zh) * 2015-09-10 2015-12-23 福建农林大学 一种复方叶下珠制剂及其在犬日粮上的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4388457A (en) 1982-02-11 1983-06-14 University Patents, Inc. Phyllanthostatin compounds
US4673575A (en) 1985-04-26 1987-06-16 Fox Chase Cancer Center Composition, pharmaceutical preparation and method for treating viral hepatitus
US4937074A (en) 1988-03-29 1990-06-26 Fox Chase Cancer Center Method of treating retrovirus infection
US5854233A (en) * 1993-09-08 1998-12-29 Pharmacy And Therapeutic Advisory Consultancy Ltd. Method of treating liver disease and like indications with vasodilating agents
US5529778A (en) * 1994-09-13 1996-06-25 Rohatgi; Surendra Ayurvedic composition for the prophylaxis and treatment of AIDS, flu, TB and other immuno-deficiencies and the process for preparing the same
US5571441A (en) 1994-11-01 1996-11-05 The Procter & Gamble Company Nutrient supplement compositions providing physiologic feedback
US5648089A (en) * 1995-07-03 1997-07-15 Shawkat; Tarek Extract solution and herbal mixture for treatment of hepatitis
US6136316A (en) 1996-04-17 2000-10-24 Dabur Research Foundation Hepatoprotective compositions and composition for treatment of conditions related to hepatitis B and E infection
US6747136B2 (en) 1996-04-19 2004-06-08 Karolinska Innovations Ab Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen
PT903148E (pt) 1997-09-21 2002-02-28 Schering Corp Terapia de combinacao para a erradicacao de rna de hcv detectavel em doentes tendo infeccao cronica pelo virus da hepatite c
GB2355932B (en) 1999-04-12 2004-01-07 Univ Madras A pharmaceutical formulation suitable for the treatment of hepatitis B, hepatitis C and other viral infections of the liver and a process for its preparation

Also Published As

Publication number Publication date
EP1176971B1 (de) 2004-09-08
JP2002543139A (ja) 2002-12-17
EP1176971A1 (de) 2002-02-06
DE50007689D1 (de) 2004-10-14
CN1364085A (zh) 2002-08-14
MXPA01010982A (es) 2003-07-21
AU4559200A (en) 2000-11-17
DE19919585A1 (de) 2000-12-07
AU4559300A (en) 2000-11-17
JP2002543140A (ja) 2002-12-17
MXPA01010980A (es) 2003-06-30
WO2000066134A1 (de) 2000-11-09
CA2372223A1 (en) 2000-11-09
US6586015B1 (en) 2003-07-01
WO2000066135A1 (de) 2000-11-09
ES2226831T3 (es) 2005-04-01
EP1176972A1 (de) 2002-02-06
PT1176971E (pt) 2005-01-31
CN1352563A (zh) 2002-06-05
ATE275411T1 (de) 2004-09-15
BR0010590A (pt) 2003-07-22
CA2372220A1 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
PT1176971E (pt) Utilizacao de phyllanthus para o tratamento de processos inflamatorios e fibroticos cronicos
BR0014890B1 (pt) sistema para alinhar dados de tratamento e/ou diagnàstico refrativo.
BR9911666A (pt) Combinação farmacêutica, uso da combinação, processo para tratamento de uma doença inflamatória em uma pessoa sofrendo de ou susceptìvel a tal doença, e, composição farmacêutica
IT1306716B1 (it) Associazione di batteri lattici e suo uso per la prevenzione e/o iltrattamento terapeutico di infezioni e di stati infiammatori.
NO20021830D0 (no) Sammensetninger egnet til å forhindre og behandle forkjölelse og influensaliknende symptomer samt fremgangsmåter vedfremstilling derav
EP2335722A3 (en) Use of gelsolin to treat infections
EP1300877A4 (en) PLASMA PROCESSING DEVICE
EP1300876A4 (en) PLASMA PROCESSING DEVICE
BRPI0110506B8 (pt) uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
BRPI0411050A (pt) composições para prevenção e tratamento de sintomas semelhantes a gripe e resfriado compreendendo zinco quelado
EP1300875A4 (en) PLASMA PROCESSING DEVICE
DK1694342T3 (da) Fremgangsmåder til anvendelse af gelsolin til behandling eller forebyggelse af bakteriel sepsis
MA26896A1 (fr) Utilisation de compositions d'antibiotiques azalides pour le traitement ou la prevention d'une infection par des bacteries ou protozoaires chez des mammiferes
PT1299395E (pt) Oxazinoquinolonas uteis para o tratamento de infeccoes provocadas por virus
DK0880964T3 (da) Aldosereduktaseinhibition til forebyggelse eller reversering af diabetisk cardiomyopati
AU2001269082A1 (en) Use of phyllanthus constituents for treating or preventing infections caused by flaviviridae
DK1326599T3 (da) Anvendelse af aivlosin til behandling eller forebyggelse af Lawsonia-infektioner i grise
BR0115983A (pt) Uso de sarp-1 para o tratamento e/ou prevenção de escleroderma
PT806957E (pt) Terapeutica de construcao para infeccao por hiv utilizando o inibidor de protease de hiv indinavir e o inibidor de transcriptase reversa 3tc
PT1079818E (pt) Composicao compreendendo il-18 e topotecano para o tratamento e /ou prevencao de cancro
PL365292A1 (en) Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2
MA26252A1 (fr) Usine flottante de traitement d'hydrocarbures.
FI20040531A7 (fi) Insuliiniresistenttien tilojen hoitaminen ja diagnosointi
WO2005044301A3 (en) Use of specific histones for the treatment of parasitic diseases
NO20011075L (no) Peptidfragmenter av kolera-toksin eller enterotoksin som vaksineadjuvanser

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO POR TER SIDO INDEVIDA, REF A RPI 2094 DE 22/02/2011

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: A61K 35/78

Ipc: A61K 36/47 (2006.01), A61P 1/16 (2006.01)

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) ART .8O COMBINADO COM ART. 11E ART. 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.